CZ280699A3 - Medicament against infertility and for increasing fertility - Google Patents

Abstract

The present invention relates to the use of a local anesthetic for production a drug that is used against infertility or increased fertility. It also relates to a pharmaceutical compound containing the same a pharmaceutically effective dose of a local anesthetic together with Pharmaceutically AcceptableHelicide Also refers to the progr increasing fertility in women using the aforementioned pharmaceutical compounds.

Description

Technical field

The present invention relates to the use of a local anesthetic for the manufacture of a medicament against infertility and for increasing fertility. It also relates to a pharmaceutical compound which comprises a pharmaceutically effective dose of a local anesthetic with a pharmaceutically acceptable vehicle. It also relates to a method of increasing fertility in women using said pharmaceutical compound.

BACKGROUND OF THE INVENTION

Infertility or reduced fertility is a problem for disabled people. IVF (tube fertilization) is a common method of treatment in infertile women. The essence of IVF treatment is as follows:

Ovulation stimulation: daily hormone injections, ultrasound examination and blood tests.

Egg collection: under local anesthesia, collection via the vagina by puncture of the ovaries under ultrasound controls.

Sperm preparation: a floating or other method to select the optimal population with the best mobility.

In vitro fertilization: Incubation of eggs and selected sperm populations in a cell incubator. Direct microscopic control of cell division and selection of the most viable blastocytes.

Embryo transfer: 2-3 of the most viable blastocytes are placed in the uterine cavity and are expected to nest in the uterine mucosa.

IVF treatment is an expensive treatment and causes psychological side effects in some couples. The technical and artificial method of attempting to conceive has disadvantages for a couple who undergo such treatment, which may also affect the relationship. Upon completion of strenuous treatment, the pregnancy rate is only 25 to 30%, leaving those who have failed with a disrupted relationship and still childless. The cost of IVF treatment is 20,000 to 25,000 SEK per menstrual cycle.

Despite several previous researches, neither the reason for infertility in endometriosis nor the lack of fertility after treatment is clear. In particular, there is an unclear relationship between mild endometriosis and reduced fertility where pelvic adhesions are absent (Mahmood, TA, Templeton A. Pathophysiology of mild endometriosis: review of literature. Human Reproduction 1990; 5: 765-784).

Patients with mucosal implants on the peritoneum have an increased number of white blood cells in the abdominal cavity and are considered to be ongoing sterile inflammation. (Haney AF, Muscato JJ, Weinberg JB: Peritoneal Fluid Cell Population in Infertility Patients. Fertil Steril 1981, 35: 696-698; Edelstam GAB, Lundquist OE, Venge P, Laurent TC: Hyaluronan and Myeloperoxidase in the Peritoneal Fluid During Genital Inflammation Inflamation 1994, 18: 13-21). The increased white blood cell count contains in vivo sensitized macrophages that secrete macrophage-derived growth factor (MDGF) and this may be explained by proliferation of uterine mucosal tissue. (Halme J, White C, Kauma S, Estes J, Haskill S. Peritoneal macrophages from patients with endometriosis release growth factor activity in Vitro. J Clin Endocrin and Metabolism. 1988; 66: 104449). Other macrophage secretory products, growth factors such as TNF and interferon, are characterized by sex cell toxicity and also have an adverse effect on the fertilization process (Halme J: Role of peritoneal inflammation in endometriosis-associated infertility. Ann NY Acad Sci 1991; 622: 266 -74).

Also, cell-free abdominal fluid is important in reduced fertility and has been shown to significantly reduce the ability of fallopian tubes to transport the egg. (Suginami H, Yano K, Watanbe K, Matsnura S: A factor in inhibiting ovum capture by the oviductal fimbriae present in endometriosis of peritoneal fluid. Fertil Steril 1986; 46: 1140-1146).

Abdominal fluid in patients with endometriosis and unexplained infertility was found to have decreased sperm movement rate (Makarand K, Oak M, Chantler EN, Vaughan Williams CA, Elstein M. Sperm survival studies in peritoneal fluid from infertile women with endometriosis and unexplained infertility. and fertility 1985; 3: 297-303). More interestingly, increased sperm phagocytosis was detected during a 24 hour incubation in an abdominal fluid tube from patients with endometriosis. (Muscato JJ, Haney AF, Weingerg JB, Sperm phagocytosis by human peritoneal macrophages: a possible cause of infertility in endometriosis. Am J Obstet Gynecol • ·

1982; 144; 503-510). In this special study, semen from different donors has been used and therefore immunological factors cannot be omitted.

SUMMARY OF THE INVENTION

The present invention is an alternative to IVF treatment of fertility in women.

Tube studies have shown that lidocaine reduces sperm phagocytosis. It can be assumed that this lidocaine effect is due to cell membrane stabilization by preventing increased sodium permeability and probably affecting ATP in the cell membrane. The cost of this treatment will be approximately 10% compared to IVF treatment, e.g.

500 SEK per menstrual cycle. There is no technical process of fertilization that could cause psychological side effects. This treatment may be tried in patients with endometriosis and / or a minor mechanical cause of infertility. It can be done while waiting for IVF and has no effect on the possibility of successful IVF treatment later.

The treatment of infertility with lidocaine has not been published in the literature. However, other pharmaceutical effects of lidocaine are known. E.g. in EP 507 160, which discloses a composition for topical application to the skin, wherein lidocaine is contained in a holding layer placed on a carrier. This preparation is used to treat neuralgia in shingles and postherpetic neuralgia.

Brief description of the pictures

As used herein, the term "endometr" means endometriosis and "end-prob" means predicted endometriosis.

Figure 1 shows schematically the number of free spermatozoa found every single day after incubation: with cell medium (A, control), cell medium and lidocaine (B), with abdominal fluid (C, control), and abdominal fluid and lidocaine ( D).

·· ··

0 0 · 0 · 0 0 0 0 0 0

0 · · · ·

0 · 000 000 • ··

Figure 2 shows schematically the number of progressively moving spermatozoa found each day after incubation: with cell medium (A, control), cell medium and lidocaine (B), with abdominal fluid (C, control), and abdominal fluid and lidocaine (D).

Figure 3 shows schematically the number of non-progressive but moving spermatozoa found every single day after incubation: with cell medium (A, control), cell medium and lidocaine (B), with abdominal fluid (C, control), and abdominal fluid and lidocaine (D).

Figure 4 shows schematically the number of living but still spermatozoa found every single day after incubation: with cell medium (A, control), cell medium and lidocaine (B), with abdominal fluid (C, control), and abdominal fluid and lidocaine (D).

Figure 5 shows schematically the number of dead spermatozoa found each day after incubation: with cell medium (A, control), cell medium and lidocaine (B), with abdominal fluid (C, control), and abdominal fluid and lidocaine ( D).

DETAILED DESCRIPTION OF THE INVENTION

Referring to Figures 1 to 6, the use of local anesthetics to manufacture a medicament for use against infertility or to enhance fertility. The local anesthetic is selected from a substance having a locally desensitizing effect. Examples of such substances are bupivacaine (1-butyl-N (2,6-dimethylphenyl) -2-piperidinecarboxamide), lidocaine (2- (diethylamino) -N- (2,6-dimethylphenyl) acetamide), mepivacaine (N- (2,6 (dimethyl-phenyl) -1-methyl-2-piperidinecarboxamide), prilocaine (N- (2-methylphenyl) -2- (propylamino) propanamide) and ropivacaine ((S) -N- (2,6-dimethylphenyl) -1-propyl-2 (piperidine carboxamide). Other local anesthetics may also be used. Preferably, lidocaine is used.

Another feature of the present invention is a pharmaceutical compound which comprises a pharmaceutically effective concentration of a local anesthetic together with a pharmaceutically acceptable vehicle. The concentration is that which has an effect on female infertility or increases fertility in a female. The dose and concentration are decided by the GP.

· 99 · 9 · 9 · 9 · 9 · 9 9 · 9 9 · 9 9 9

9

9 9 9

The concentration of the active ingredient is at least 5 pg / ml. 100 to 2000 pg in 1 to 20 ml, preferably 118 pg, are used. The dose to be administered is at least 100 pg, in particular 1000 pg. The compound is preferably administered into the abdominal cavity, preferably via the fallopian tubes. The local anesthetic is defined above.

The active ingredient is mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredient suitable for the treatment method described herein. In addition, if desired, compounds that contain minor amounts of excipients, such as wetting and emulsifying agents, pH adjusters, and the like, may be used to enhance the effectiveness of the active ingredient.

The pharmaceutical compound of the present invention also includes the pharmaceutically acceptable salts of the compounds herein. Pharmaceutically acceptable salts include the additional acid salts formed with inorganic acids such as hydrochloric or phosphoric acid, or with organic acids such as acetic, tartaric or mandelic acids.

Physiologically acceptable carriers are well known to those skilled in the art. Examples of liquid carriers are sterile aqueous solutions that no longer contain any additives to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH, saline, or both, such as phosphate-buffered saline. Aqueous solutions may contain more than one buffer salt as well as salts such as potassium and sodium chloride, dextrose, propylene glycol, polyethylene glycol, and other solutions.

The compounds may also form hyaluronan, which is a viscous substance such as formate gel. Hyaluronan allows a slow release of the active ingredient, which is advantageous for the treatment according to the invention, since fertilization can occur up to 24 hours after ovulation. Another advantage is that hyaluronan has a sperm stimulating effect (Zimmerman ER, Tiny E, Robertson KR, Nakajima ST, Kim H: Seed preparation with the Sperm Select system versus washing technique. Fertil Steril 1994; 61: 269-275).

Infertility is generally not considered a disease. The invention also includes a process for treating infertility in a female by a pharmaceutical compound of the invention, which is characterized by being administered via the fallopian tubes.

ΦΦ

Φ Φ · Φ Φ Φ • Φ Φ ·

ΦΦΦ

ΦΦΦΦ φ φ · ··

Φ Φ · Φ Φ

ΦΦΦ i · Φ Φ

Φ φ Φ Φ ΦΦΦ • ΦΦ Φ Φ »ΦΦ ΦΦ ΦΦ ΦΦ

In particular, the invention relates to a cosmetic and untreated method of treating infertility or increasing fertility, wherein a) ovulation is diagnosed, b) local anesthetic treatment is administered as soon as ovulation according to a) is expected.

Treatment is preferably performed via the fallopian tubes. The following steps are advantageous:

Spontaneous ovulation: primary treatment during the normal menstrual cycle. Stimulation only in patients with anovulatory cycle and primarily clomifene (tablet) stimulation, which is simple and inexpensive, requires one blood sample after ovulation to verify that ovulation has occurred during the treatment cycle.

LH (Luteinizing Hormone) Test: LH increases 24-36 hours prior to ovulation are diagnosed with a home urine sample test.

Pertubation: If the LH test is positive, the drug is administered via the fallopian tubes eg 10 ml of 100 pg / ml lidocaine in physiological NaCl or Ringer's solution during normal gynecological examination. No numbness is required.

Fertilization: No artificial treatment. The couple attempt to achieve pregnancy in the normal way by sexual intercourse at home after treatment with fallopian tubes.

Sperm survival was found to be absent, demonstrating that spermatozoa are not affected by lidocaine, and this has also been demonstrated in other studies. (Bennett SJ, Bolton V, Parson J. The effects of lignocaine on human sperm motility. J Assised Reprod. & Genetics 1992; 9: 271-3). The same seems to be true for eggs as high lidocaine levels were measured without any problems with fertilization or fetal development. (Bailey-Pridham DD; Cook CL; Reshef E; Hurst HE; Drury K; Yussman MA. Follicular Fluid lidocain levels during transvaginal oocyte retrieval. Fertil Steril 1990; 53: 171-173). The highest levels were 118 μg / ml, which means that a dose of 1000 μg lidocaine for incubation in a test tube could be diluted eg with 100 pg / ml in 10 ml isotonic fluid. This concentration will now be used for clinical studies of successful pregnancy after pertubation 24 hours prior to ovulation to ensure better sperm survival.

Lidocaine has been used for many years without any adverse reactions during pregnancy, as has also been shown in an animal study. (Ramazzotto J,

Curro FA, Paterson JA, Tanner P, Coleman M. Toxicological Assessment of Lidocaine in the Pregnant Rat. J Dent Res 1985; 64: 1214-1218) and can therefore be used to treat infertility in patients with endometriosis.

The invention is illustrated by the following example. All technical and scientific terms used herein, unless otherwise defined, have the same meaning as commonly understood by one of ordinary skill in the art. The methods used herein are well known to those skilled in the art unless otherwise specified. The publications mentioned herein are incorporated by reference.

DETAILED DESCRIPTION OF THE INVENTION

Example 1

Reduction of sperm phagocytosis in abdominal fluid in women with endometriosis.

This study was conducted to further analyze leukocyte function in reduced fertility during endometriosis and also to look for a possible therapeutic approach. To exclude immunological effects, only one sperm donor participated in the experiments. The prepared sperm samples were incubated with non-centrifuged abdominal fluid from healthy women and women with endometriosis to evaluate the importance of sperm phagocytosis in reduced fertility during endometriosis. The number of viable spermatozoa in incubation was calculated daily for five days with and without the presence of a local anesthetic, which was added in search of a method of reducing the activity of the abdominal leukocyte populations.

Material and methods

Patients

Women: The patients were divided into three different groups. The control group (n = 9, mean age = 38.5 years) consisted of women undergoing laparoscopic sterilization or women with unclear abdominal pain. Control groups had a laparoscopic finding normal with anatomically normal uterus and fallopian tubes.

The study group included women who underwent laparoscopy to identify the cause of infertility or suffer from abdominal pain and were diagnosed with endometriosis (n = 11, mean age = 34.5 years). In this group, there was a laparoscopic diagnosis in 8 patients and an anamnestic probability of endometriosis in 3 patients who had not developed any endometriosis implant that could be detected laparoscopic.

44 • 4 • 4

4 4 · ·

4444 44

44 «3 4 ·

• 44

44

Men: The sperm donor was a healthy 38-year-old male with normal fertility with 2-3 days of sexual restraint before each sperm collection. Sperm samples were prepared using a float technique to select the optimal population (Russel LD, Rogers BJ. Improvement in the quality and fertilization potential of the human sperm population using the rise technique. J Androl 1987; 8:25).

Peritoneal fluid samples obtained during laparoscopy

Blood samples were collected after anesthetics were administered to patients to later determine hyaluronan, which is used as a marker of ongoing inflammation to exclude small pelvic inflammatory disease. At the beginning of laparoscopy with safe instruments in the abdominal cavity, all available peritoneal fluid in the Douglas chamber was aspirated through a suction aspirator through a Teflon catheter (1.7 mm diameter, Optinova, Godby, Finland) and then mixed immediately after collection with 10 IU heparin / ml in a teflon bottle. (Olive DL, Weinberg JB, Haney AF. Peritoneal macrofages and infertility: association between cell number and pelvic pathology. Fertil Steril 1985; 44: 772-777). The amount of peritoneal fluid was determined by weighing on electric scales. Teflon was selected as a material that exhibits low adhesion to mammalian cells. (Grinnell F, Milam M, Srere PA. Studies on cell adhesion. Arch Biochem Biophys 1972; 153: 193-198). Heparin was used as an anticoagulant to prevent white blood cells from clumping. (Makarand et al. 1985) Previously, citrate was used (Edelstam et al. 1994), which had adverse effects on sperm viability during incubation. All samples were collected with patient consent and the sample process was approved by the Ethics Committee, Faculty of Medicine, University of Uppsala, Sweden.

Incubation of sperm and peritoneal fluid

Teflon tubes were used for all incubations, see below, which were performed in a humidified cell incubator:

(a) cell medium (1 ml), sperm (10 ⁶ in 1 ml cell medium) and 0.1 ml NaCl.

b) cell medium (1 ml), sperm (10 ⁶ in 1 ml cell medium) and 0.1 ml lidocaine 10 mg / ml (Xylocain ®, ASTRA).

c) sperm (10 ® in 1 ml cell medium), peritoneal fluid (1 ml) and 0.1 ml NaCl.

99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99

99

d) sperm (10 ⁶ in 1 ml cell medium), 0.1 mt lidocaine (10 mg / ml) and peritoneal fluid (1 ml).

Earl's cell medium (Sigma) with 0.35% BSA (bovine serum albumin)

The remaining portion of the peritoneal fluid was centrifuged and the supernatant frozen (-20 ° C) for subsequent hyaluronan determination. (Edelstam et al. 1994) The tubes were analyzed daily for five days and the following parameters were measured in all A to D incubations up to 100 sperm counts:

number of free sperms that did not adhere to white blood cells number of sperms with progressive mobility number of sperms with non-progressive motion number of sperms that are still but live number of dead sperms

The percentage of viable peritoneal white blood cells was also determined daily using trypan blue.

Results

In particular, it was found that there were statistically significantly fewer phagocytosed spermatozoa in the tubes that were incubated with peritoneal fluid and lidocaine (p <0.02). The spermatozoa were captured in large clusters of white blood cells and some were apparently phagocytosed, thus reducing the number of free functional sperm.

Sperm survival with and without endometriosis: After a two-day incubation, statistically significantly more free spermatozoa were found when incubated with peritoneal fluid from the normal group compared to the endometriosis group. (Kruskal Wallis p < 0.014).

Sperm survival with and without lidocaine: There were no adverse effects on sperm survival and there was no statistically significant difference between sperm incubation with or without lidocaine after 24 or 48 hours. P (Wilcoxon) values are shown in Tables I and II.

Sperm survival with and without peritoneal fluid and lidocaine, regardless of diagnosis: Progressive motility decreases much more in the absence of peritoneal fluid (Figure 2) compared to incubation of sperm alone.

Sperm survival with and without peritoneal fluid in the endometriosis group: In the presence of peritoneal fluid and lidocaine, statistically significantly more free sperm was found, especially after two days of incubation in the endometriosis group. See Figure 1 and Table II.

More dead sperm were detected in lidocaine incubations in both diagnosed groups. Figure 5, Table II.

Concentrations of hyaluronan in the peritoneal fluid showed no signs of an ongoing inflammatory process; that it was confirmed that all patients were healthy.

•

Table 1: P-values for various parameters recorded during incubations when comparing incubations with and without lidocaine. Data after 24 hour incubation.

0 0 0 0 0 0 0 0

0000

00 00 00 00 0 0 0 0 0 0

0 0 0 0 0 0 • * 00,000,000

0 0 0 0

000 00 00 00

Sperm + Jidokain Sperm + peritoneal fluid, normal, iJdokain Sperm + peritoneal fluid, endometriosis jjidokain All patients without certain diagnosis jjidokain loosely, not adhered to white blood cells all free with and without lidocaine 0.59 0.27 progressive mobility 0.88 0.046 (a) 0.67 0.11 non-progressive mobility 0.59 0.59 0.79 0.58 stationary 0.76 0.40 0.31 0.18 immovable (dead) 0.28 0.14 0.09 0.024 b viability white blood cells 0.26 0.29 0.92 sperm adhered on the white surface blood cells no adhered on the white surface blood cells in both groups 0.68 0.80

a) more progressive sperm motility ph incubation with lidocaine

b) more dead in the lidocaine group

Table II: P-values for various parameters recorded during incubations when comparing incubations with and without lidocaine. Data after 48 hour incubation.

· · · · · · · ·

Sperm jjidokain Sperm + peritoneal fluid, normal, + Jidokain Sperm + peritoneal fluid, endometriosis + _lidokain All patients without certain diagnosis + Jidokain loosely, not adhered to white blood cells 1.0 0.018 d 0.0021 (d) progressive mobility None progressive mobility with a without lidocaine 1.00 0.89 0.95 non-progressive mobility 0.18 0.025 (c) 0.21 0.021 (c) stationary 0.78 0.26 0.58 0.22 immovable (dead) 0.50 0.038 (c) 0.003 (c) 0.00025 (c) viability white blood cells 0.78 0.51 0.57 sperm adhered on the white surface blood cells 1.00 0.53 0.63

c) more with lidocaine

(d) more free in the lidocaine group

··

0 0 · 0 0 0

0 0

0 0

0000 00

0 0 0 0 0 0 0 00

00 0 0 0 0

0 0 0 • 000 000

0

00

The present invention includes the effect of lidocaine on sperm survival and the effect on sperm phagocytosis by white blood cells of the abdominal cavity in a tube during incubation for 5 days.

This study involves only one sperm donor to avoid various immunological combinations that would be an uncontrollable factor in the experiments. This study also monitored sperm survival for up to five days, while previous studies looked at sperm survival for 24 hours. Furthermore, not only the number of free, non-absorbed sperm, but also the number of progressive or stationary motility as well as the number of living, dead or free (i.e., not adhering to the white blood cell surface) sperm counted.

In the present invention, the previous findings of Muscato et al. 1982 and refer to reduced fertility in patients with endometriosis due to sperm absorption. Increased peritoneal macrophage uptake capacity in patients with endometriosis has also been demonstrated by fluorescent beads. (Samejima T, Masuzaki H, Ishimaru T, Yamabe T. Activity of Peritoneal Macrophages in Endometriosis. Asia Oceania J Obstet Gynaecolo 1989, 15: 175-181).

Other studies on sperm absorption do not take into account the problem of loss of white blood cells that adhere more to other material (Grinell et al. 1972). Makarand et al. 1985 used a glass container to store peritoneal fluid. The glass exhibits the greatest adhesion of white blood cells (Grinell et al. 1972) and is used to separate macrophages (Smedsroed B, Pertoft H.). J Leukocyte Biol. 1985; 38). Muscato et al. in 1989 he chose polypropylene, which is a better option than glass in terms of cell adhesion problem, but less suitable than teflon.

It is believed that the observed amount of dead spermatozoa in incubation, with lidocaine, is due to decreased sperm absorption in the presence of lidocaine, since no adverse effects on spermatozoa were detected when spermatozoa alone with and without lidocaine. This also explains the finding of increased non-progressive sperm motility when incubated with lidocaine (Figure 2). This reduction in progressive mobility in the absence of peritoneal fluid suggests that the peritoneal fluid contains substances necessary to maintain sperm function.

99

9 9 10 «9 9»

999 99 «·

9 «

99

9 9 9

9 9

9 9

9 · 9999 99

9 ·

9 ·

As mentioned in the introduction, the fallopian tube fibers are continuously moistened with peritoneal fluid, which in the case of patients with endometriosis reduces the capacity to catch the egg. (Suginami et al. 1986). As shown in this and previous study, white blood cells in the peritoneal fluid of patients with endometriosis are more effective in sperm absorption. (Muscato et al. 1982). Therefore, in women with endometriosis, there may be two factors that contribute to their reduced fertility. This study also shows the possibility of using the effect of lidocaine to reduce sperm absorption.

In summary, this study demonstrates reduced sperm absorption in the presence of lidocaine. This phenomenon must be further monitored in randomized clinical studies of pertubation with saline or lidocaine solutions in saline prior to ovulation (period of elevated LH)

While the present invention is described in conjunction with the preferred compounds and substances, it should be understood that certain substitutions and modifications may be made without departing from the scope of the following claims.

Claims (8)

PATENT CLAIMS ·· · «· *> · * * * * * «« «« « Use of a local anesthetic for the manufacture of a medicament characterized in that it is used against infertility or to increase fertility. Use according to claim 1, characterized in that the local anesthetic is selected from the group consisting of bupivacaine, lidocaine, mepivacaine, prilocaine and ropivacaine. 3. A pharmaceutical composition comprising a pharmaceutically effective concentration of a local anesthetic with a pharmaceutically acceptable vehicle. The pharmaceutical composition of claim 3, wherein the pharmaceutically effective concentration is at least 5 µg / ml. The pharmaceutical composition according to claim 3, wherein the local anesthetic is selected from the group consisting of bupivacaine, lidocaine, mepivacaine, prilocaine and ropivacaine. The pharmaceutical composition of claim 3, wherein the pharmaceutically acceptable vehicle comprises saline NaCl or Ringer's solution. Pharmaceutical composition according to any one of claims 3 to 6, characterized in that it contains hyaluronan. A method of enhancing fertility in women using a pharmaceutical agent according to claim 3, characterized in that the pharmaceutical agent is administered to the abdominal cavity preferably via the fallopian tubes.